Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: A Pediatric Oncology Group study

Journal of Clinical Oncology

Volumn 16, Issue 3, 1998, Pages 945-952

  Saylors III, Robert L ^a   Stewart, Clinton F ^a   Zamboni, William C ^a   Wall, Donna A ^a   Bell, Beverly ^a   Stine, Kimo C ^a   Vietti, Teresa J ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG RESPONSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEPHROBLASTOMA; NEUROBLASTOMA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0031934032     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.3.945     Document Type: Article

References (20)

1. Slichenmeyer WJ, Rowinsky EK, Donehower RC, et al: The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85:271-291, 1993
2. Liu LF: DNA topoisomerase poisons as antitumor drugs. Ann Rev Biochem 38:351-375, 1989
3. Hertzberg RP, Caranfa MJ, Hecht SM: On the mechanism of topoisomerase I inhibition by camptothecin: Evidence for binding to an enzyme-DNA complex. Biochemistry 28:4629-4638, 1989
4. Hsiang Y-H, Hertzberg R, Hecht S, et al: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873-14878, 1985
5. Hsiang Y-H, Liu LF: Identification of mammalian DNA topoisomerase 1 as an intracellular target of the anticancer drug camptothecin. Cancer Res 48:1722-1726, 1988
6. Mattern MR, Hofmann GA, McCabe FL, et al: Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F104864). Cancer Res 51:5813-5816, 1991
7. Tubergen DG, Stewart CF, Pratt CB, et al: Phase I trial and pharmacokinetic and pharmacodynamic study of topotecan using a five-day course in children with refractory solid tumors: A Pediatric Oncology Group study. J Pediatr Hematol Oncol 18:352-361, 1996
8. Finkelstein J, Hittle R, Hammond D: Evaluation of a high-dose cyclophosphamide regimen in childhood tumors. Cancer 23:1239-1242, 1969
9. Stewart CF, Baker SD, Heideman RL, et al: Clinical pharmacodynamics of continuous infusion topotecan in children: Systemic exposure predicts hematologic toxicity. J Clin Oncol 12:1946-1954, 1994
10. Lalonda RL: Pharmacodynamics, in Evans WE, Schentag JJ, Jusko WJ (eds): Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. Vancouver, WA, Applied Therapeutics, 1992, pp 414-433
11. Metzler CM, Weiner DL: PCNONLIN User's Guide (ed 4). Lexington, KY, Statistical Consultants, 1992
12. Eckardt JR, Burris HA, Rodriguez GA, et al: A phase I study of the topoisomerase I and II inhibitors topotecan and etoposide. Proc Am Soc Clin Oncol 12:137, 1993 (abstr)
13. Miller AA, Hargis JB, Fields S, et al: Phase I study of topotecan and cisplatin in patients with advanced cancer (CALGB 9261). Proc Am Soc Clin Oncol 12:399, 1993 (abstr)
14. Murren JR, Anderson S, Fedele J, et al: Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer. J Clin Oncol 15:148-157, 1997
15. Moore MJ, Hardy RW, Thiessen JJ, et al: Rapid development of enhanced clearance after high-dose cyclophosphamide. Clin Pharmacol Ther 44:622-628, 1988
16. Graham MI, Shaw IC, Souhami RL, et al: Decreased plasma half-life of cyclophosphamide during repeated high-dose administration. Cancer Chemother Pharmacol 10:192-193, 1983
17. Chang TKH, Weber GF, Crespi CL, et al: Differential activation of cyclophosphamide and ifosfamide by cytochromes p-450 2B and 3A in human liver microsomes. Cancer Res 53:1-9, 1993
18. Pratt CB, Stewart C, Santana VM, et al: Phase I study of topotecan for pediatric patients with malignant solid tumors. J Clin Oncol 12:539-543, 1994
19. Houghton PJ, Stewart CF, Zamboni WC, et al: Schedule dependent efficacy of camptothecins in models of human cancer. Ann NY Acad Sci 803:188-201, 1996
20. Yule SM, Boddy AV, Cole M, et al: Cyclophosphamide metabolism in children. Cancer Res 55:803-809, 1995